The document discusses guidelines from JNC 7 and ESH/ESC for treating hypertension. JNC 7 recommends initially treating stage 1 hypertension with thiazide diuretics and considering other drug classes. For stage 2 hypertension, it recommends starting with a two-drug combination, usually including a thiazide. ESH/ESC guidelines state that most patients will require two or more drugs to reach blood pressure goals and recommend considering initial therapy with a low-dose two-drug combination. Both emphasize lifestyle changes and medication combinations or adjustments to achieve blood pressure control.
Calcium channel blockers are useful treatments in the management of hypertension. In this presentation by Dr Vivek Baliga, we look at the added benefits of newer types of CCBs in treating high blood pressure. Read more from Dr Baliga here - http://drvivekbaliga.net
Calcium channel blockers are useful treatments in the management of hypertension. In this presentation by Dr Vivek Baliga, we look at the added benefits of newer types of CCBs in treating high blood pressure. Read more from Dr Baliga here - http://drvivekbaliga.net
Association and prevalence of different comorbidities in hypertension and management with focus guidelines with benefits & choice of different antihypertensives in different comorbidities.
Individualized Webcam facilitated and e-Classroom USMLE Step 1 Tutorials with Dr. Cray. 1 BMS Unit is 4 hr. General Principles and some Organ System require multiple units to complete in preparation for the USMLE Step 1 A HIGH YIELD FOCUS IN Biochemistry / Cell Biology, Microbiology / Immunology and the 4 P’s-Phiso, Pathophys, Path and Pharm. Webcam Facilitated USMLE Step 2 Clinical Knowledge and Clinical Skills diadactic tutorials /1 Unit is 4 hours, individualized one-on-one and group sessions, Including all Internal Medicine sub-sub-specitialities. For questions or more information.. drcray@imhotepvirtualmedsch.com
After attending this presentation audience will be able to:
•Define Blood pressure, Normal BP and Hypertension
•Classify Hypertension
•Enlist Predisposing factors of Hypertension
•Describe the consequences of Hypertension
•Explain/plan that how to avoid Hypertension
Presentations by Tawfiq Choudhury and Rocco Hadland from the second webinar of the Mastering Cholesterol webinar series on Thursday 11 May 2023, focusing on Statins.
GLP-1 is an incretin (hormone that increases insulin secretion in response to a meal), which is a 30-amino acid peptide secreted in response to the oral ingestion of nutrients by intestinal L cells.
GLP-1 receptors (GLP-1R) are located in islet cells, central nervous system, and other organs. GLP-1 is metabolized by the enzyme dipeptidyl peptidase-4 (DPP-4).
Incretin effect is a phenomenon whereby a glucose load delivered orally produces a much greater insulin secretion than the same glucose load administered intravenously.
This presentation is an overview of the entire GLP-1 system, followed by an introduction to leveraging its therapeutic potential using GLP-1 analogues (Exenatide, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide) and DPP-4 inhibitors (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Anagliptin, Teneligliptin, Alogliptin, Trelagliptin, Omarigliptin).
Shashikiran Umakanth delivered this talk at Manipal on 30th November, 2015
Chair and Presenter, Javed Butler, MD, MPH, MBA, Alice Y.Y. Cheng, MD, FRCPC, and Muthiah Vaduganathan, MD, MPH, discuss heart failure in this CME activity titled “How I Think, How I Treat: Cardiology-Focused Perspectives on Using SGLT2 Inhibitors to Optimize Outcomes in Patients With Heart Failure.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/3zqI6yD. CME credit will be available until December 5, 2023.
Association and prevalence of different comorbidities in hypertension and management with focus guidelines with benefits & choice of different antihypertensives in different comorbidities.
Individualized Webcam facilitated and e-Classroom USMLE Step 1 Tutorials with Dr. Cray. 1 BMS Unit is 4 hr. General Principles and some Organ System require multiple units to complete in preparation for the USMLE Step 1 A HIGH YIELD FOCUS IN Biochemistry / Cell Biology, Microbiology / Immunology and the 4 P’s-Phiso, Pathophys, Path and Pharm. Webcam Facilitated USMLE Step 2 Clinical Knowledge and Clinical Skills diadactic tutorials /1 Unit is 4 hours, individualized one-on-one and group sessions, Including all Internal Medicine sub-sub-specitialities. For questions or more information.. drcray@imhotepvirtualmedsch.com
After attending this presentation audience will be able to:
•Define Blood pressure, Normal BP and Hypertension
•Classify Hypertension
•Enlist Predisposing factors of Hypertension
•Describe the consequences of Hypertension
•Explain/plan that how to avoid Hypertension
Presentations by Tawfiq Choudhury and Rocco Hadland from the second webinar of the Mastering Cholesterol webinar series on Thursday 11 May 2023, focusing on Statins.
GLP-1 is an incretin (hormone that increases insulin secretion in response to a meal), which is a 30-amino acid peptide secreted in response to the oral ingestion of nutrients by intestinal L cells.
GLP-1 receptors (GLP-1R) are located in islet cells, central nervous system, and other organs. GLP-1 is metabolized by the enzyme dipeptidyl peptidase-4 (DPP-4).
Incretin effect is a phenomenon whereby a glucose load delivered orally produces a much greater insulin secretion than the same glucose load administered intravenously.
This presentation is an overview of the entire GLP-1 system, followed by an introduction to leveraging its therapeutic potential using GLP-1 analogues (Exenatide, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide) and DPP-4 inhibitors (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Anagliptin, Teneligliptin, Alogliptin, Trelagliptin, Omarigliptin).
Shashikiran Umakanth delivered this talk at Manipal on 30th November, 2015
Chair and Presenter, Javed Butler, MD, MPH, MBA, Alice Y.Y. Cheng, MD, FRCPC, and Muthiah Vaduganathan, MD, MPH, discuss heart failure in this CME activity titled “How I Think, How I Treat: Cardiology-Focused Perspectives on Using SGLT2 Inhibitors to Optimize Outcomes in Patients With Heart Failure.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/3zqI6yD. CME credit will be available until December 5, 2023.
European Society of Hypertension 2013 Hypertension guidelines presentation in...JAFAR ALSAID
Summary of the European Society of Hypertension 2013 Hypertension Guidelines presented during the Eighth Hypertension and Cardiovascular highlight session in Bahrain on Sept. 11th 2013.
Essential Hypertension By Raheef Alatassi
Definition & classifications
Prevention & detection & importance
Causes
HTN in pregnancy
Management
Goals of treatment
Classes of drugs & side effects
Specific management in e.g. IHD,DM
HTN emergency & urgency with management
This presentation deals with the most common antihypertensive drugs used in our day-to-day practice. The common 4 ABCDs (Angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, diuretics)
Combination Therapy In Hypertension - Dr Vivek Baliga PresentationDr Vivek Baliga
Dr Vivek Baliga of Baliga Diagnostics, Bangalore, discusses the common combination therapies used in the management of hypertension in clinical practice.
newer drug combinations in management of hypertension,esp in presence of CAD, making them more potent anti-hypertensives, with lesser side effects especially pedal edema
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Best Ayurvedic medicine for Gas and IndigestionSwastikAyurveda
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
1. JNC 7 - Algorithm for treatment of hypertension Hypertension with compelling indications Stage 1 hypertension (SBP 140-159 or DBP 90-99 mmHg) Thiazide-type diuretics for most May consider ACE inhibitor, ARB, -blocker, CCB, or combination Stage 2 hypertension (SBP ≥160 mmHg or DBP ≥100 mmHg) 2-drug combination for most (usually thiazide-type diuretic and ACE inhibitor or ARB or -blocker or CCB) Drug(s) for compelling indications Other antihypertensive drugs (diuretics, ACE inhibitor, ARB, -blocker, CCB) as needed Not at goal BP Lifestyle modifications JNC 7 VII, Hypertens. 2003;42:1206-1252. Not at goal BP (<140/90 mmHg or <130/80 mmHg for those with diabetes or chronic kidney disease) Initial drug choices Hypertension without compelling indications Optimize dosages or add additional drugs until goal BP is achieved Consider consultation with hypertension specialist For Internal Use Only
2. ESH/ESC guidelines Pharmacological Treatment of Hypertension Consider : Blood pressure level before treatment Absence or presence of TOD and risk factors Two-drug combination at low dose Choose between : Single agent at low dose If goal BP not achieved : Previous agent at full dose Switch to different agent at low dose Previous combination at full dose Add a third drug at low dose If goal BP not achieved : Two-three drug combination Two-three drug combination ESH/ESC Guidelines. J Hypertens 2003; 21: 1011-1053 For Internal Use Only
3.
4.
5.
6.
7.
8.
9.
10.
11. First line therapy Compelling indication for others Compelling indication for others Compelling indication for others - 2 drug combo 2 drug combo Low dose Diuretics Any of 5 (A,A,B,C,D) Thiazide-type Diuretics WHO-ISH ESH-ESC JNC 7 For Internal Use Only JNC 7 Report . JAMA 2003; 289: 2560-2572 ESH/ESC Guidelines. J Hypertens 2003 ; 21: 1011-1053 Guidelines Sub-Committee. 1999 WHO/ISH. J Hypertens 1999; 17:151–183
12. Recommended combinations Di ACE I CCB ARB B B WHO-ISH ESH-ESC JNC VII Di + any Di + ACE I/ ARB/ CCB/ B For Internal Use Only JNC 7 Report . JAMA 2003; 289: 2560-2572 ESH/ESC Guidelines. J Hypertens 2003 ; 21: 1011-1053 Guidelines Sub-Committee. 1999 WHO/ISH. J Hypertens 1999; 17:151–183
13.
14. SBP Control in Trials * 10604 M FACET Micro HOPE CAPPP INSIGHT HOT VALUE STOP-2 UKPDS LIFE RENAAL IDNT IRMA ABCD 130 140 150 160 170 180 190 200 mmHg 120 Diabetics B T ALLHAT 1 HOPE PROGRESS CAPPP INSIGHT NORDIL HOT STONE STOP-2 LIFE ALLHAT 2 ANBP2 INVEST SCOPE ASCOT VALUE All patients 130 140 150 160 170 180 190 200 mmHg B T * Most patients under ≥ 2 drugs Mancia G and Grassi G, J Hypert 2002;20:1461-1464 For Internal Use Only
15. Combination Therapy in Large Trials 0 10 20 30 40 100 90 80 70 60 50 Average VA SYST-EUR STOP-2 STOP-1 SHEP NORDIL MRC II MRC I MAPHY INSIGHT HOT 90 LIFE EWPHE COOPE ANBP 62% 100% 41% 55% 66% 45% 52% 51% 34% 48% 54% 60% 90% 35% 93% 33% % ALLHAT 41% INVEST 82% Updated from Coca A. J Cardiovasc Pharmacol 1999; 34 (Suppl 3): 29-35 For Internal Use Only
16. Multiple Antihypertensive Agents Are Often Needed to Achieve Target BP 1 No. of Antihypertensive Agents 2 3 4 SBP 140/DBP 90 ALLHAT 7 SBP 135/DBP 85 IDNT 6 MAP 92 AASK 5 DBP 80 HOT 4 MAP 92 MDRD 3 DBP 75 ABCD 2 DBP 85 UKPDS 1 Target BP (mm Hg) Trial DBP- diastolic blood pressure MAP - mean arterial pressure ; SBP- systolic blood pressure 1. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713. 2. Estacio RO et al. Am J Cardiol. 1998;82:9R-14R. 3. Lazarus JM et al. Hypertension. 1997;29:641-650. 4. Hansson L et al. Lancet. 1998;351:1755-1762. 5. Kusek JW et al. Control Clin Trials. 1996;16:40S-46S. 6. Lewis EJ et al. N Engl J Med. 2001;345:851-860. 7. ALLHAT. JAMA . 2002;288:2998-3007. For Internal Use Only
17. Compliance to Treatment Related to Daily Number of Pills Prescribed Average number of daily pills 0 10 20 30 40 50 60 70 1 2 3 8 Compliance to treatment (%) Mancia G et al. Am J Hypertens 1997 ; 10: 153S-158S For Internal Use Only
18. Fixed-dose Combination Therapy Increases Compliance to Treatment Persistence rates of one pill of lisinopril/HCTZ in fixed-combination vs two separate pills of lisinopril and HCTZ 100 95 90 85 80 75 70 65 60 55 50 0 1 2 3 4 5 6 7 8 9 10 11 12 Months Persistence (%) 68.7 57.8 18.8% Lisinopril/HCTZ (1 pill) Lisinopril and HCTZ (2 pills) Dezii CM . Manag Care 2000; 9 (Suppl): s2-s6 For Internal Use Only
19.
20.
21. The 3 Classes of Diuretics and Their Primary Sites of Action in the Nephron For Internal Use Only Adapted from: Oparil S and Weber MA. Hypertension.Elsevier/Sanders 2nd ed. 2005; L ip G and Bakris G. Handbook Hypertension Management. CMG 2006
22.
23.
24.
25. The Mechanism of Calcium-Channel Blockade For Internal Use Only Adapted from: Oparil S and Weber MA. Hypertension.Elsevier/Sanders 2nd ed. 2005; L ip G and Bakris G. Handbook Hypertension Management. CMG 2006
26.
27.
28. The Mechanism of Beta-Blockade Reduced cardiac output Reduced blood pressure Impulse Smooth muscle presynaptic sympathetic neurons Cardiac tissue (contains beta 1 receptors) Increased bronchial resistance and vasoconstriction Impulse Smooth muscle presynaptic sympathetic neurons Tissue of the peripheral blood vessels, smooth muscle cells or lungs (contains beta 2 receptors) Beta-blocker Nonadrenaline or adrenaline Beta 1 receptors Beta 2 receptors Reduced heart rate and force of constriction Beta 1 receptor blocked by beta-blocker Beta 2 receptor blocked by beta-blocker Adapted from: Oparil S and Weber MA. Hypertension.Elsevier/Sanders 2nd ed. 2005; L ip G and Bakris G. Handbook Hypertension Management. CMG 2006 For Internal Use Only
29.
30.
31. The Mechanism of Alpha-Blockade Total peripheral resistance increased Blood Pressure rises Constriction of blood vessel Impulse Smooth muscle presynaptic sympathetic neurons Vascular smooth muscle cell Total peripheral resistance decreased Blood pressure falls Blood vessel remains dilated Impulse Smooth muscle presynaptic sympathetic neurons Alpha 1 receptor blocked so muscle cells do not contract Alpha 1 receptor blocker Nonadrenaline or adrenaline Alpha 1 receptors Alpha 2 receptors For Internal Use Only Adapted from: Oparil S and Weber MA. Hypertension.Elsevier/Sanders 2nd ed. 2005; L ip G and Bakris G. Handbook Hypertension Management. CMG 2006
32.
33. The Mechanism of Action of ACE-inhibitors Angiotensin I Bradykinin ACE Inhibitor ACE (from lungs) Angiotensinogen (from liver) Renin (from kidney) Angiotensin II Inactive kinins Vasodilation Blood pressure decreases Retention of salt and water Increased aldosterone Increased blood volume Increased total Peripheral resistance Vasoconstriction Blood pressure increase Bradykinin pathway RAA System For Internal Use Only Adapted from: Oparil S and Weber MA. Hypertension.Elsevier/Sanders 2nd ed. 2005; L ip G and Bakris G. Handbook Hypertension Management. CMG 2006
34.
35. Mechanism of Action of Angiotensin II Receptor Blockers (ARBs) Adapted from Unger T. Am J Cardiol 2002; 89 (suppl):3A-10A. AT 1 Receptor Na reabsorption Aldosterone release Sympathetic outflow Vasopressin secretion Vasoconstriction Vascular and cardiac hypertrophy Angiotensinogen Angiotensin I Angiotensin II Non-ACE enzymes (cathepsin, chymase) Renin Bradykinin ACE Inactive Fragments AT 2 Receptor Vasodilation Growth inhibition Apoptosis Blood Pressure ARBs For Internal Use Only
36. Pharmacologic Characteristics of ARBs HTN HTN, post MI, CHF HTN HTN, Nephropathy T2DM + HTN, Morbi-Mortality reduction and stroke prevention in HTN with LVH HTN HTN, CHF HTN, Nephropathy T2DM + HTN Indications Digoxin no no Rifampin, Fluconazole no no no Drug interract 24h 6h 12-18h 2h 5-9h 9h 11-15h T 1/2 Minimal yes none minimal yes none none Food effect 0.5-1h 2-4h 1-2h 3-4h 3h 3-4h 1.5-2h Tmax 42-58% 25% 26% 33% 13% 15% 60-80% Bioavail Boeh Ingelh Novartis/ Beaufour Menar/Sank MSD Solvay AstZen/Tak SA/BMS Company Telmisartan (Micardis) Valsartan (Diovan) Olmesartan (Benicar) Losartan (Cozaar) Eprosartan (Teveten) Candesartan (Atacand) Irbesartan (Avapro/ Aprovel) For Internal Use Only Oparil S and Weber MA. Hypertension.Elsevier/Sanders 2nd ed. 2005; L ip G and Bakris G. Handbook Hypertension Management. CMG 2006